Skip to main content
. 2019 Jan 15;11(1):96. doi: 10.3390/cancers11010096

Figure 2.

Figure 2

Immunization with the SP-SA-E7-4-1BBL DNA vaccine shows prophylaxis against TC-1 tumor: (A) Endpoint tumor incidence. Groups (n = 5) of five 5- to 6-week-old C57BL/6 mice were immunized on shaved abdominal skin with 1 µg of DNA using gene gun system, and a week later they received a booster immunization under the same conditions. One week later, mice were challenged with 5 × 104 TC-1 cells in the right flank by subcutaneous injection. Tumor incidence is reported as the fraction of mice bearing tumors of diameter ≥2 mm. (B) Tumor volume after subcutaneous injection of TC-1 cells in C57BL/6 mice. Tumor volumes are represented by mean ± SEM. Mice were euthanized when the tumor volume was higher than 1500 mm3. * p < 0.05, SP-SA-E7-4-1BBL and CRT-E7wt compared with E7wt, SP-SA-4-1BBL and empty vector. Two-way ANOVA and post-hoc Tukey’s test were performed.